Introduction
have only recently been initiated, the present review is limited to β-lactam antibiotics and new quinolones whose pharmacokinetics can be clearly judged as transporter-dependent. In this review, the transporter prefixes are indicated as m: mouse, r: rat, h: human.
Pharmacokinetics of β-Lactam Antibiotics
The β-lactam antibiotics display a broad spectrum of antibacterial activity with a relatively low risk of allergic and toxic reactions. After intravenous or oral administration, despite the similarity in their chemical structures, various β-lactam antibiotics exhibit marked differences in their oral bioavailability, tissue distribution and elimination from the body, which cannot be explained in terms of their physicochemical properties.
1) Intestinal absorption
Although it has long been believed that most drugs are absorbed through the gastrointestinal epithelium by a simple diffusion mechanism depending on their lipophilicity, much direct and indirect evidence for the participation of transporter-mediated absorption has been accumulated. The mammalian SCL transporter, PEPT1 (SLC15A1) transports nutritional oligopeptides across the luminal membrane into small-intestinal epithelial cells at a microclimate pH of 6.1 to 6.8. This transporter is driven by an inwardly directed proton gradient and catalyzes the cotransport of its substrates with H + . Although the natural substrates are di-and tripeptides, PEPT1 has a very broad substrate specificity and transports orally effective peptide-mimetic drugs, such as β-lactam antibiotics, ACE inhibitors, the antineoplastic agent bestatin and the The basolateral peptide transporter mediates the efflux of substrates from the intracellular space to the portal vein and enables unidirectional transport through intestinal epithelial cells.
Irie et al. 10 suggested that reducing the affinity of drugs for the basolateral peptide transporter on the intracellular surface in human intestinal epithelial Caco-2 cells would lead to more efficient absorption of small peptides and peptide-mimetic drugs taken up via PEPT1.
2) Elimination from the kidney
Numerous organic anions, including endogenous metabolites, drugs and xenobiotics, are excreted into the urine through the renal proximal tubules and/or via glomerular filtration. The active excretion process, except filtration, is achieved via unidirectional transcellular transport.
This involves the uptake of drugs into the tubular cells from the blood across the basolateral membrane, followed by extrusion across the brush-border membrane into urine. Figure 1 shows transporters expressed in the human kidney. 1 Some are located on the basolateral membrane (blood side), while the others are located on the brush-border membrane side.
These transporters play important roles in the tubular secretion and/or reabsorption of drugs.
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Most β-lactam antibiotics (penicillins and cephalosporins, and carbapenems) are excreted into urine in nonmetabolized form, and in addition to the glomerular filtration of the antibiotics unbound with plasma albumin, their renal tubular secretion via the para-aminohippuric acid (PAH) transporter and probenecid-sensitive system is thought to be an important pathway of renal clearance. 12, 13 Some cephalosporins, such as cephaloridine, have severe nephrotoxicity, and it is suggested that their toxic effect is related to the transport systems in the renal proximal tubules.
14 Transport of β-lactam antibiotics mediated by renal organic anion transporter has an important influence on their pharmacokinetics and toxicokinetics. Among human organic anion transporters, OAT1 (SLC22A6) and OAT3 (SLC22A8) are PAH/dicarboxylate exchangers, and are localized on the basolateral side of the proximal tubules, whereas OAT4 (SLC22A11) is localized on the apical side of the proximal tubules. [15] [16] [17] Jariyamato et al. 18 demonstrated that benzylpenicillin and cephaloridine are taken up by rOAT1 (Slc22A6) expressed in Xenopus laevis oocytes. They also demonstrated that PAH uptake by rOTA1
was inhibited by most β-lactam antibiotics in a competitive manner, whereas other antibiotics, such as gentamicin, streptomycin and vancomycin, which do not contain anionic moieties, did not interact with rOAT1. Cells expressing rOAT1 were most susceptible to cephaloridine cytotoxicity. 18 Uwai et al. 19 demonstrated that rOAT1 transports urinary-excreted cefazolin, cefotiam and cephalexin, and these antibiotics inhibit PAH uptake by rOAT1, whereas biliary-excreted cefoperazone does not, and they also showed that rOAT1 plays an important role in transport of cephalosporins and PAH in the rat kidney. These results suggest that rOAT1 is the major organic anion transporter in the kidney, and is responsible for the renal excretion of β-lactam antibiotics in rats.
A recent report 20 indicated that the OAT3 mRNA level was well correlated with the elimination rate of the free fraction of cefazolin in patients with mesangial proliferative glomerulonenephritis, which is most common form of primary renal disease. In contrast, the correlation with the level of OAT1 mRNA was lower.
Ueo et al. 21 demonstrated that the uptakes of cephaloridine, cefdinir and cefotiam by OAT3 stably transfected into HEK293 cells were 35-to 50-fold greater than those by control cells. In contrast, the uptake of these antibiotics by HEK-OAT1 was within two-fold of that by control cells. 21 These results indicate that OAT3 plays a much more important role than OAT1 in the renal basolateral transport of cephalosporins in humans.
With respect to the substrate recognition and transport activity of OAT family members, there are some species differences.
In humans, β-lactam-exporting transporters localized in the apical membrane of the proximal tubules include OAT4, P-gp (MDR1, ABCB1), multidrug resistance-associated proteins 2 (MRP2, ABCC2) and 4 (MRP4, ABCC4), sodium-dependent inorganic phosphate transporter (NPT1, SLC17A1), and OAT v 1. [22] [23] [24] [25] [26] [27] [28] [29] [30] OAT4 is an apical organic anion/dicarboxylate exchanger, which mainly functions under physiological conditions as an apical pathway for the reabsorption of some organic anions from urine into tubular cells, driven by an outwardly directed dicarboxylate gradient, probably with coupling to apical organic efflux transporters, such as MRP2, NPT1 and, possibly, the human homologue of OATv1.
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NPT1 expressed in Xenopus laevis oocytes transports estradiol-17β-glucuronide, PAH, benzylpenicillin, faropenem, indomethacin and uric acid and an has affinity for several organic anions, including 2-ketoglutaric acid, β-lactam antibiotics (ampicillin, cefazolin, cephalexin), benzoic acid, lactic acid, probenecid and phenol red. 27, 28 Since the uptake of faropenem by mNPT1 is reduced in the presence of high concentrations of chloride, 27 NPT1 is suggested to participate in the secretion of β-lactam antibiotics from tubular cells to urine.
Therefore, NPT1 acts as a multifunctional transporter for the sodium-dependent reabsorption of phosphate from urine into tubular cells and simultaneously for sodium-independent secretion of organic anions, including β-lactam antibiotics, from tubular cells to urine. 28 ATP-driven drug efflux pumps, such as P-gp and MRP2, are localized on the apical membrane of tubular cells and have been thought to handle the excretion of a wide range of substrates into urine. 29, 30 However, the renal clearance of cefpiramide, which is mainly excreted into bile, was reported to be increased 2-fold in Eisai hyperbilirubinemic rats (EHBR) with a deficiency of rMRP2 (Abcc2) compared with that in normal rats, after intravenous administration. 31 Renal clearance of cefoperazone and cephalexin showed no significant difference between normal rats and EHBR (unpublished observation). These results suggest that rMRP2 makes no significant contribution to the renal excretion of β-lactam antibiotics.
The human peptide transporters PEPT1 and PEPT2 (SLC15A2), which exhibit only about 50% homology in amino acid sequence, are localized on the brush-border membrane of the proximal tubule. PEPT1 is expressed in the early part of the proximal tubule (pars convolute), whereas PEPT2 is expressed further along the proximal tubule (pars recta).
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These transporters may play roles in the reabsorption of di-and tri-peptides and peptide-mimetics, such as β-lactam antibiotics, from urine into tubular epithelial cells. 32 The affinities of β-lactam antibiotics are higher for PEPT2 and lower for PEPT1. 
3) Tissue distribution
The values of steady-state volume of distribution (Vdss) of ß-lactam antibiotics have been reported to be around 0.3 L/kg in animals and humans, suggesting that tissue distribution of these antibiotics is limited to the interstitial fluid space of tissues. 47, 48 This is due to little activity of uptake transporters in non-eliminating tissues (except lung), in contrast to intestine, kidney and liver described above, resulting in poor antibacterial efficacy for intracellular infection.
Groneberg et al. 
3-1) Blood-brain and blood-cerebrospinal barriers
Matsushita et al. demonstrated that the concentration of cefodizime in the intracellular fluid of the brain is less than the unbound plasma concentration, although the participation of an uptake system from blood to brain was observed. 55 Kikuchi et al. found that benzylpenicillin, as well as PAH, is effluxed from the rat brain. 56 These results suggest participation of some kind of efflux system in the BBB for ß-lactam antibiotics. The limited distribution into the central nervous system (CNS) of ß-lactam antibiotics after administration to humans, as well as animals, is due to (a) the limited, possibly molecular-size-dependent, ability to cross the barrier of CNS, the degree of plasma protein binding and ionization, 57 and/or (b) the efflux from CNS to blood via an active transport system. 58 As shown in Fig. 1 , transporters expressed at the brain capillary endothelial cells mediate uptake from the bloodstream to the brain for essential nutrients, especially hydrophilic nutrients and some types of nutrient-mimetic drugs, and efflux from brain to blood for endogenous and/or exogenous compounds, i.e., they form a part of the blood-brain barrier (BBB). 55, 56, 58 The discovery of the brain-to-blood efflux transporter, P-gp, encoded by multidrug resistance gene (MDR1), in 1992 58, 59 completely changed the concept of the BBB from a static lipoidal membrane barrier to a dynamic interface that regulates movement of compounds between brain and blood by means of active transport mechanisms. The most convincing evidence of P-gp-mediated efflux is the demonstration of significantly increased brain distribution of numerous drugs in mdr1a and/or mdr1b gene knockout mice. 60, 61 Many studies on the significance of P-gp at the BBB using mdr1a/b knockout mice have been performed for many drugs. However, it has been reported that ß-lactam antibiotics are not transported by P-gp, suggesting that the limited entry of ß-lactam antibiotics from blood into brain across the BBB may be due to participation of another efflux transporter(s).
In addition to P-gp, various transporters, including SLC family members, such as OATs, and ABC family members, such as BCRP and MRPs, have been found to mediate efflux of endogenous and/or exogenous compounds from the brain to the blood stream. 62 Among OAT family members, rOAT3 has been reported to be localized at the abluminal membrane of brain capillary endothelial cells. 56, 63, 64 Almost all β-lactam antibiotics, as well as benzylpenicillin and PAH, are substrates of rOAT3 and therefore are likely to be actively transported by OAT3 from brain to plasma across the BBB. Regarding transport at the luminal membrane, it is likely that ATP-driven active transporters (MRPs) other than P-gp remove anionic drugs, including ß-lactam antibiotics, from endothelial cells, transporting them to the circulating blood. MRP1, MRP2, MRP4, MRP5 and MRP6, which mediate transport in this direction, are expressed at the BBB. 65, 66 Low concentrations of ß-lactam antibiotics in cerebrospinal fluid (CSF) are often presumed to be the result of poor BBB and blood-CSF barrier (BCSFB) penetration.
Fishman 67 suggested that a saturable and probenecid-sensitive system transports penicillin from CSF. Later, Spector and Lorenzo 68 demonstrated that the active efflux pump was located in the choroid plexus and was saturable at high penicillin concentrations. This saturable efflux mechanism was later confirmed to operate for the efflux of other ß-lactam antibiotics.
OAT3 and PEPT2 are expressed in the choroid plexus, which forms the BCSFB. Kuroda et al. 69 demonstrated that cefaclor is cleared from CSF more rapidly than cephalexin after intracerebroventricular administration in rats. They suggested that cefaclor and cephalexin are eliminated from the CSF by different transporters, although both are substrates of rOAT3 and rPEPT2, and that rapid elimination of cefaclor from the CSF occurs via a benzylpenicillin-sensitive mechanism distinct from rOAT3, whereas cephalexin is removed by a GlySar-sensitive transporter.
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PEPT2 also functions as an efflux pump for removal of endogenous or exogenous peptide-like chemicals, such as β-lactam antibiotics. 70 Neither PEPT2 mRNA nor PEPT2 protein is expressed in the brain capillary endothelial cells that form the rat BBB. 71 Recently, Shen et al. demonstrated, using mPEPT2-deficient mice, that PEPT2 acts as an efflux transporter in the removal of cefadroxil from CSF, and that the process is unidirectional from CSF to blood. 72 These findings by Kuroda et al. 69 and Shen et al. 72 suggest that cefaclor and cephalexin do not share the same efflux transport mechanism in choroid plexus and that OAT3 and PEPT2 both play important roles in regulating the CSN concentration of ß-lactam antibiotics.
Therefore, brain capillary endothelial cells and choroid plexus selectively regulate the uptake of compounds essential for brain function from blood to brain and CSF by means of influx transporters, and prevent toxic or non-essential compounds from entering the brain from blood, or eliminate them from the brain, by means of efflux transporters.
3-2) Blood-placenta barrier
In the placenta, there is thought to be a tissue-barrier system but, little is known as to the mechanism by which the placenta carries out this barrier function. Fetal blood is separated from the maternal blood circulation by polarized cells, i.e. syncytiotrophoblasts, which possesses carrier-mediated transport systems similar to those in the renal proximal tubules and intestinal epithelial cells. The placenta probably plays the primary role in the elimination of toxic compounds from the fetus. Cha et al. found high levels of mRNA expression of OAT4 in the placenta and the kidney, whereas rOAT2 and hOAT3 are not expressed in the placenta 22 The expression of OAT1 in the placenta is extremely weak or absent, and OAT4 is predominantly expressed in the placenta among OAT isoforms. 22 Since OAT4 is a tertiary active organic anion/dicarboxylate exchanger under physiological conditions, it might be responsible for the elimination and detoxication of estrone sulfate and other organic anions, such as NSAIDs, diuretics, sulfobromophthalein, benzylpenicillin and bile acids, which interact with this transporter.
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Two other excretory pathways have been identified in the placenta. The xenobiotics transporters ABCP, 73 a member of the ABC superfamily, and OCT3 74 may also contribute to the placenta barrier.
Pharmacokinetics of New Quinolones
New furoroquinolone antibacterial agents (new quinolones) are well absorbed from the gastrointestinal tract and distributed to various tissues with high distribution volume.
The distribution volumes of sparfloxacin, lomefloxacin and ofloxacin are about 6.0, 1.46 and 1.54 L/kg, respectively, 75 being higher than those of β-lactam antibiotics (about 0.3 L/kg).
Grepafloxacin and olamufloxacin exhibit particularly high concentrations in the lung after oral administration. 76 The lung concentration of unchanged olamufloxacin is about nine times higher than that in plasma after oral administration (5 mg/kg), whereas other quinolones showed values close to unity. 76 Sasabe et al. 77 and Murata et al. 76 demonstrated that the uptake of grepafloxacin and olamufloxacin by isolated rat lung cells was temperature-dependent, saturable, stereospecific, and at least Na + -dependent. The uptake of both quinolones was inhibited by other quinolones, including sparfloxacin. It should be noted that clarithromycin has been reported to be taken up by carrier-mediated active transport into isolated rat lung cells. 78 Although identification of the transporter(s) of quinolones and clarithlomycin remains to be done, carrier-mediated system(s) may at least partially account for the efficient distribution of grepafloxacin, olamufloxacin and clarithlomycin, and could provide a specific route for drug delivery to the lung.
Some quinolones exhibit very low distribution into the brain compared with that into other peripheral tissues. 79 The efflux across the blood-brain barrier (BBB) may be an important determinant for quinolones, rather than the transport across the BCSFB. 80 Tamai et al. 81 Very similar efflux transport by P-gp at the BBB was demonstrated for olamufloxacin 82 and a new prodrug-type quinolone, prulifloxacin, 83 the brain-to-plasma concentration ratio (Kp) in mdr1a/1b gene-deficient mice being significantly higher for prulifloxacin than that in the normal mice.
Accordingly, the very low brain distribution of most quinolone antibacterial agents is a consequence of the action of multiple efflux transporters, including P-glycoprotein, MRP1, and other unknown anion exchange transporter(s).
Most quinolones are mainly excreted into urine after oral administration, though grepafloxacin and olamufloxacin exhibit greater hepatobiliary transport than other quinolones. [84] [85] [86] [87] The biliary excretion of the unchanged forms of grepafloxacin [84] [85] [86] and olamufloxacin 87 in EHBR amounted to less than 30% of that in normal rats, whereas the 3-glucuronide (a main metabolite of both quinolones) was hardly excreted into the bile in EHBR. ATP dependence was observed in the uptake of grepafloxacin by bile canalicular membrane vesicles (CMV), although the extent was not very marked, whereas no ATP-dependent uptake was observed by CMV prepared from EHBR. The uptake of grepafloxillin glucuronide by CMV from normal rats showed a marked ATP dependence, whereas there was little ATP-dependent uptake in EHBR. [84] [85] [86] These results indicate that at least a part of the transport of quinolones and a major part of the glucuronide transport across the bile canalicular membrane in rats involve a primary active transport mechanism mediated by rMRP2.
Griffiths et al. 88 Similar studies by Naruhashi et al. 89 demonstrated that grepafloxacin showed secretory-directed transport which was decreased by cyclosporin A, an inhibitor of P-glycoprotein, and probenecid, an inhibitor of anion transport systems. This suggested contributions of P-glycoprotein and anion-sensitive transporter(s). In mdr1a(-/-)/1b(-/-) mice, the intestinal secretory clearance was smaller than that in wild-type mice after intravenous administration of grepafloxacin. Moreover, the absorption from an intestinal loop in mdr1a(-/-)/1b(-/-) mice was larger than that in wild-type mice. 89 Accordingly, it appears that some quinolones are transported by secretory transporters, including P-glycoprotein. The involved transporters function in vivo not only to transport grepafloxacin from blood to intestine, but also to limit its intestinal absorption.
Oral bioavailablity of fluoroquinolones is relatively good; indeed, some of them are completely absorbed, even though they are secreted into the intestine by efflux transporters such as P-gp and MRPs, as indicated above. This suggests that uptake transport system(s) participate in the intestinal absorption of fluoroquinolones. This hypothesis remains to be tested.
Drug interactions after treatment with rifampin
A number of clinically important drug interactions with rifampin have been reported to result from its powerful induction of intestinal cytochrome P450 3A4. 90, 91 It was recently reported that concomitant administration of rifampin at a dose of 600 mg/day for 10 days in healthy volunteers reduced digoxin plasma concentrations substantially after an oral single-dose (1 mg) administration compared with the plasma-time profile without rifampin treatment. 92 The effect was less pronounced after intravenous administration of digoxin.
The oral bioavailability of digoxin decreased by 30% during rifampin therapy. When duodenal biopsies obtained before and after administration of rifampin were analyzed, it was found that rifampin treatment increased the content of intestinal P-gp 3.5+/-2.1-fold, which correlated well with the change in the area under the curve (AUC) after oral digoxin, but not after intravenous digoxin. Since rifampin is a known inducer of cytochrome P450 enzymes (e.g. CYP3A4), as well as P-gp, the induction of intestinal CYP3A4 protein would be expected to increase intestinal metabolism, so that a decrease of plasma dogoxin level after rifampin treatment might be predicted. Although CYP3A in duodenal samples was enhanced 4.4-fold, there was no correlation between the AUC of digoxin and CYP3A4 expression of individual volunteers. 92 These data strongly indicate that P-gp modulates intestinal digoxin absorption, leading to low drug concentrations in individuals with high P-gp expression and high concentrations in those with low P-gp expression. 92 Accordingly, rifampin-mediated P-gp induction is associated with a reduction of plasma digoxin.
Conclusions
With the help of great progress in key pharmaceutical technologies, we are now entering a new era in drug delivery. Although several drug transporters have been utilized as novel delivery systems, transport mechanisms for the majority of drugs are still unknown (Fig. 2) .
Therefore, we have to identify all the participating transporters in order to establish the potential utility of this approach to drug delivery. We require an efficient screening system to pick appropriate transporter(s) that can be used for delivery and also for target and/or lead discovery. Another aspect that demands careful consideration is pharmacokinetic drug-drug interaction at the transporter and the effects of single-nucleotide polymorphisms (SNPs) of drug transporters. Recent progress in these areas has been described elsewhere. 
